- Home - Valneva
Valneva is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need
- R D - Valneva
Our R D portfolio primarily reflects our scientific, technical and clinical competencies in vector-borne infectious diseases and in both bacterial and viral vaccines
- Investors - Valneva
Investor Relations Team Campus Bio-Ouest 6, Rue Alain Bombard 44800 Saint-Herblain, France T: +33 2 28 07 37 10 investors@valneva com
- Valneva Announces U. S. FDA Approval of World’s First Chikungunya . . .
The U S Food and Drug Administration (FDA) has approved IXCHIQ®, Valneva’s single-dose, live-attenuated vaccine indicated for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 18 years of age and older who are at increased risk of exposure to CHIKV
- About Us - Valneva
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs
- About Us - Valneva
Valneva est une société spécialisée dans le développement, la production et la commercialisation de vaccins prophylactiques contre des maladies infectieuses générant d’importants besoins médicaux
- Valneva Reports Positive Six-Month Antibody Persistence and Safety . . .
Saint-Herblain (France), June 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ®, in 304 children Partially funded by the Coalition for
- Careers - Valneva
Our achievements are based on our Company's culture, which is characterized by respect, dedication and motivation
|